Editas Medicine, Inc. (EDIT) Earnings History
Annual and quarterly earnings data from 2013 to 2025
Loading earnings history...
EDIT EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
EDIT Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | 100.0% | -777.2% | -733.7% |
| 2023 | 92.2% | -216.6% | -196.1% |
| 2022 | 67.9% | -1146.3% | -1118.3% |
| 2021 | 80.2% | -756.1% | -753.6% |
Download Data
Export EDIT earnings history in CSV or JSON format
Free sign-in required to download data
Editas Medicine, Inc. (EDIT) Earnings Overview
As of May 7, 2026, Editas Medicine, Inc. (EDIT) reported trailing twelve-month net income of -$160M, reflecting +37.5% year-over-year growth. The company earned $-1.80 per diluted share over the past four quarters.
Looking at the long-term picture, EDIT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2013.
Editas Medicine, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CRSP (-$569M net income, -16569.8% margin), BEAM (-$80M net income, -57.2% margin), NTLA (-$413M net income), EDIT has comparable earnings metrics. Compare EDIT vs CRSP →
EDIT Earnings vs Peers
Earnings metrics vs comparable public companies
EDIT Historical Earnings Data (2013–2025)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$160M | +32.5% | $0 | $-1.80 | - | - |
| 2024 | -$237M | -54.7% | -$251M | $-2.88 | -733.7% | -777.2% |
| 2023 | -$153M | +30.5% | -$169M | $-2.02 | -196.1% | -216.6% |
| 2022 | -$220M | -14.5% | -$226M | $-3.21 | -1118.3% | -1146.3% |
| 2021 | -$193M | -66.0% | -$193M | $-2.85 | -753.6% | -756.1% |
| 2020 | -$116M | +13.3% | -$135M | $-1.98 | -127.8% | -148.6% |
| 2019 | -$134M | -21.6% | -$141M | $-2.47 | -651.4% | -686.4% |
| 2018 | -$110M | +8.6% | -$114M | $-2.33 | -344.3% | -356.1% |
| 2017 | -$120M | -23.8% | -$120M | $-2.98 | -876.5% | -873.6% |
| 2016 | -$97M | -33.3% | -$97M | $-3.02 | -1605.5% | -1605.6% |
See EDIT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EDIT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EDIT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEDIT — Frequently Asked Questions
Quick answers to the most common questions about buying EDIT stock.
Is EDIT growing earnings?
EDIT EPS is $-1.80, with earnings growth accelerating to +37.5%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-160M.
What are EDIT's profit margins?
Editas Medicine, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are EDIT's earnings?
EDIT earnings data spans 2013-2025. The accelerating earnings trend is +37.5% YoY. Historical data enables comparison across business cycles.